Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease
Open Access
- 20 April 2026
- journal article
- Published by Elsevier in Annals of Hepatology
- p. 102206
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology, Republic of the Philippines
- Regione Autonoma Friuli Venezia Giulia
- European Commission
This publication has 40 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitisEndocrine, 2021
- Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisHepatology, 2019
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver diseaseHepatology, 2015
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Repeatability of magnetic resonance elastography for quantification of hepatic stiffnessJournal of Magnetic Resonance Imaging, 2010
- Histopathologic Variability Between the Right and Left Lobes of the Liver in Morbidly Obese Patients Undergoing Roux-en-Y BypassClinical Gastroenterology and Hepatology, 2007
- Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease†Hepatology, 2006